Abstract
6030 Background: The incidence of oropharyngeal cancer (OPC) has increased 5% per year over the past decade due to a rise in human papilloma virus (HPV)-driven OPC. HPV+ OPC is clinically and molecularly distinct from HPV- head and neck squamous cell carcinomas (HNSCC). However, there are currently no validated therapeutic targets for HPV+ HNSCC. Methods: Reverse phase protein array (RPPA) was performed on HNSCC tumors from The Cancer Genome Atlas to measure cancer-associated pathways and targets. Differences in individual markers and proteomic pathway scores between HPV+ and HPV– tumors were assessed by t-test in the overall group and for the subset of OPC. Results: Significant proteomic differences were observed in 14 HPV+ and 186 HPV- HNSCC. Of 160 proteins, the top marker overexpressed in HPV+ HNSCC was p16, an established clinical biomarker of HPV status (p<0.0001). Other cell cycle proteins significantly dysregulated were p27; cyclins B1, E1 and E2; and E2F1 (higher in HPV+) and pRb (lower in HPV+) ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
